Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024)
Capricor Therapeutics' (CAPR) quarterly FCF Margin came in at 137.33% in Q4 2024, down 3679.0% year-on-year from 3.84% in Q1 2024, and up 73.34% quarter-over-quarter from 515.18% in Q3 2024.
Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 137.33% for Q4 2024.
- On a quarterly basis, FCF Margin fell 3679.0% year-over-year to 137.33% in Q4 2024; TTM through Sep 2025 was 563.94%, a 42966.0% decrease from a year earlier, with the FY2024 full-year figure at 184.83%, down 7796.0% from the prior year.
- FCF Margin climbed to 137.33% in Q4 2024 per CAPR's latest filing, from 515.18% in the prior quarter.
- Across five years, FCF Margin topped out at 129.32% in Q1 2023 and bottomed at 18558.95% in Q3 2020.
- The 5-year median for FCF Margin is 453.73% (2024), against an average of 2735.15%.
- Across the five-year window, FCF Margin plunged 1739659 bps in 2020 and surged 188979 bps in 2021, its largest moves.
- Year by year, FCF Margin stood at 7142.52% in 2020, then soared by 67 bps to 2370.08% in 2021, then surged by 67 bps to 791.34% in 2022, then jumped by 87 bps to 100.53% in 2023, then slumped by 37 bps to 137.33% in 2024.
- Per Business Quant, the three latest CAPR FCF Margin figures stand at 137.33% (Q4 2024), 515.18% (Q3 2024), and 310.94% (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -137.33% |
| Sep 30, 2024 | -515.18% |
| Jun 30, 2024 | -310.94% |
| Mar 31, 2024 | -18.77% |
| Dec 31, 2023 | -100.53% |
| Sep 30, 2023 | -146.53% |
| Jun 30, 2023 | -243.87% |
| Mar 31, 2023 | 129.32% |
| Dec 31, 2022 | -791.34% |
| Sep 30, 2022 | -392.27% |
| Jun 30, 2021 | -2,370.08% |
| Mar 31, 2021 | -8,247.46% |
| Dec 31, 2020 | -7,142.52% |
| Sep 30, 2020 | -18,558.95% |
| Jun 30, 2020 | -4,259.87% |
| Mar 31, 2020 | -656.01% |
| Dec 31, 2019 | -803.71% |
| Sep 30, 2019 | -1,162.36% |
| Jun 30, 2019 | -433.14% |
| Mar 31, 2019 | -697.47% |